Placebo Response Hurts MoonLake In Psoriatic Arthritis
Sonelokimab follows a mid-stage slam-dunk in hidradenitis suppurativa with a rather more equivocal result in a different immune condition in the ARGO study.
Sonelokimab follows a mid-stage slam-dunk in hidradenitis suppurativa with a rather more equivocal result in a different immune condition in the ARGO study.